Brokers Set Expectations for TVTX FY2026 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Analysts at HC Wainwright issued their FY2026 EPS estimates for Travere Therapeutics in a research report issued to clients and investors on Tuesday, November 3rd. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.90) for the year. HC Wainwright has a “Buy” rating and a $67.00 price objective on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Travere Therapeutics’ Q4 2026 earnings at $0.39 EPS, FY2027 earnings at $2.14 EPS, FY2028 earnings at $4.43 EPS, FY2029 earnings at $5.17 EPS and FY2030 earnings at $6.84 EPS.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Monday, November 2nd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.49). The business had revenue of $224.56 million for the quarter, compared to analyst estimates of $195.29 million. Travere Therapeutics had a negative return on equity of 185.69% and a negative net margin of 18.66%. Travere Therapeutics’s revenue was up 36.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.28 EPS.

Other research analysts have also issued reports about the company. Citigroup raised their price target on Travere Therapeutics from $70.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a report on Friday, September 18th. TD Cowen increased their target price on Travere Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group raised their target price on Travere Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Piper Sandler restated an “overweight” rating on shares of Travere Therapeutics in a report on Monday, August 17th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Travere Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $68.60.

Travere Therapeutics Stock Performance

TVTX stock opened at $52.42 on Thursday. The business’s fifty day moving average is $58.12 and its 200-day moving average is $46.79. The company has a quick ratio of 3.99, a current ratio of 3.00 and a debt-to-equity ratio of 26.72. The company has a market cap of $5.03 billion, a P/E ratio of -40.64 and a beta of 1.11. Travere Therapeutics has a twelve month low of $22.59 and a twelve month high of $68.73.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, CEO Eric Dube sold 243,735 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $53.82, for a total value of $13,117,817.70. Following the sale, the chief executive officer directly owned 432,886 shares in the company, valued at approximately $23,297,924.52. This trade represents a 36.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Peter Heerma sold 8,282 shares of Travere Therapeutics stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $65.07, for a total transaction of $538,909.74. Following the transaction, the executive vice president directly owned 117,066 shares in the company, valued at approximately $7,617,484.62. This represents a 6.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,294,029 shares of company stock valued at $79,454,261. Corporate insiders own 4.44% of the company’s stock.

Institutional Trading of Travere Therapeutics

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Travere Therapeutics by 53.4% during the second quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after acquiring an additional 211 shares in the last quarter. Fifth Third Bancorp acquired a new position in Travere Therapeutics in the first quarter valued at about $35,000. Allworth Financial LP acquired a new position in Travere Therapeutics in the second quarter valued at about $47,000. Integrated Wealth Concepts LLC acquired a new position in Travere Therapeutics in the second quarter valued at about $70,000. Finally, Rockefeller Capital Management L.P. increased its holdings in shares of Travere Therapeutics by 1,604.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 2,642 shares of the company’s stock worth $101,000 after acquiring an additional 2,487 shares in the last quarter.

More Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $72 from $70 and reiterated a Buy rating, signaling continued confidence in the stock’s potential. Canaccord Genuity recommendations
• Neutral Sentiment: Guggenheim lowered its target to $78 from $89 but maintained a Buy rating, leaving its outlook positive while reflecting a more cautious valuation. Guggenheim recommendations
• Neutral Sentiment: A recent technical analysis noted TVTX rebounded after reaching its 200-day moving average, a level investors may view as support. Travere’s 200-day moving average reversal
• Negative Sentiment: Travere’s third-quarter results showed a loss, despite higher revenue, adding a fundamental concern alongside analyst optimism. Travere Q3 results

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.